nach oben

Rheumatology International

Erschienen in:

01.09.2005 | Short Communication

The effect of interleukin-1 blockade on fatigue in rheumatoid arthritis—a pilot study

verfasst von: Roald Omdal, Ragnar Gunnarsson

Erschienen in: Rheumatology International | Ausgabe 6/2005

Einloggen, um Zugang zu erhalten

Abstract

Fatigue occurs in many patients with rheumatoid arthritis (RA) and other chronic inflammatory diseases and may be defined as an overwhelming sense of tiredness, lack of energy, and feeling of exhaustion. It can be restrictive and severely disabling. We recently found more than 3/4 of systemic lupus erythematosus patients to be significantly affected by this phenomenon. We hypothesized that fatigue in patients with RA might be comparable to sickness behavior in animals possibly caused by disturbances in interleukin-1 beta signaling pathways and thus accessible to blockade by biologic agents. This study compared measures of disease behavior and fatigue symptoms in eight RA patients before and at three time points during treatment with daily administration of anakinra.

Wolfe F, Hawley DJ, Wilson K (1996) The prevalence and meaning of fatigue in rheumatic diseases. J Rheumatol 23:1407–1417PubMed

Koike T, Kazuma K, Kawamura S (2000) The relationship between fatigue, coping behavior, and inflammation in patients with rheumatoid arthritis. Mod Rheumatol 10:141–149CrossRef

Krupp LB, LaRocca NG, Muir J, Steinberg AD (1990) A study of fatigue in systemic lupus erythematosus. J Rheumatol 17:1450–1452PubMed

Tench CM, McCurdie I, White PD, D’Cruz DP (2000) The prevalence of fatigue in systemic lupus erythematosus. Rheumatology 39:1249–1254CrossRefPubMed

Omdal R, Mellgren SI, Koldingsnes W, Jacobsen EA, Husby G (2002) Fatigue in patients with systemic lupus erythematosus: lack of associations to serum cytokines, antiphospholipid antibodies, or other disease characteristics. J Rheumatol 29:482–486PubMed

Comi G, Leocani L, Rossi P, Colombo B (2001) Physiopathology and treatment of fatigue in multiple sclerosis. J Neurol 248:174–179CrossRefPubMed

Kurzrock R (2001) The role of cytokines in cancer-related fatigue. Cancer [Suppl] 92:1684–1688

Krupp LB, Pollina DA (1996) Mechanisms and management of fatigue in progressive neurological disorders. Curr Opin Neurol 9:456–460PubMed

Kelley KW, Hutchison K, French R et al (1997) Central interleukin-1 receptors as mediators of sickness. In: Moore PM, Lahita RG (eds) Neuropsychiatric manifestations of systemic lupus erythematosus. Ann N Y Acad Sci 823:234–246PubMed

10.

Rinehart J, Hersh E, Issell B, Triozzi P, Buhles W, Neidhart J (1997) Phase 1 trial of recombinant human interleukin-1 beta (rhIL-1 beta), carboplatin, and etoposide in patients with solid cancers: Southwest Oncology Group Study 8940. Cancer Invest 15:403–410PubMed

11.

Farrar WL, Killian PL, Ruff MR, Hill JM, Pert CB (1987) Visualization and characterization of interleukin-1 receptors in brain. Endocrinology 139:459–463

12.

Konsman JP, Blond D, Vigues S (2000) Neurobiology of interleukin-1 receptors: getting the message. Eur Cytokine Netw 11:699–702PubMed

13.

Carrié A, Jun L, Bienvenu T et al (1999) A new member of the IL-1 receptor family highly expressed in hippocampus and involved in X-linked mental retardation. Nature Genetics 23:25–31PubMed

14.

Arnett FC, Edworthy SM, Bloch DA et al (1988) The American Rheumatism Association 1987 revised criteria for the classification of rheumatoid arthritis. Arthritis Rheum 31:315–324PubMed

15.

http://www.das-score.nl/www.das-score.nl/DAS-frame-1.htm

16.

Krupp LB, LaRocca NG, Muir-Nash J, Steinberg AD (1989) The fatigue severity scale. Application to patients with multiple sclerosis and systemic lupus erythematosus. Arch Neurol 46:1121–1123PubMed

17.

Bresnihan B (2001) The prospect of treating rheumatoid arthritis with recombinant human interleukin-1 receptor antagonist. Bio Drugs 15:87–97

18.

Guyatt GH, Townsend M, Berman LB, Keller JL (1987) A comparison of Likert and visual analogue scales for measuring change in function. J Chron Dis 40:1129–1133PubMed

19.

Wang B, Gladman DD, Urowitz MB (1998) Fatigue in lupus is not correlated with disease activity. J Rheumatol 25:892–895PubMed

20.

Bruce IN, Mak VC, Hallett DC, Gladman DD, Urowitz MB (1999) Factors associated with fatigue in patients with systemic lupus erythematosus. Ann Rheum 58:379–381

21.

Omdal R, Waterloo K, Koldingsnes W, Husby G, Mellgren SI (2003) Fatigue in patients with systemic lupus erythematosus: the psychosocial aspects. J Rheumatol 30:283–287PubMed

22.

Schiller JH, Storer BE, Witt PL et al (1991) Biological and clinical effects of intravenous tumor necrosis factor-α administered three times weekly. Cancer Res 51:1651–1658PubMed

23.

Layé S, Lundkvist J, Bartfai T (1999) Cytokines in the brain. In: Thèze J (ed) The cytokine network and immune functions. Oxford University Press, New York, pp 262–269

24.

Greenberg DB, Gray JL, Mannix CM, Eisenthal S, Carey M (1993) Treatment-related fatigue and serum interleukin-1 levels in patients during external beam irradiation for prostate cancer. J Pain Symptom Manage 8:196–200PubMed

25.

Riemsa RP, Rasker JJ, Taal E, Griep EN, Wouters JMGW, Wiegman O (1998) Fatigue in rheumatoid arthritis: the role of self-efficacy and problematic social support. Br J Rheumatol 37:1042–1046CrossRefPubMed

26.

Belza BL (1995) Comparison of self-reported fatigue in rheumatoid arthritis and controls. J Rheumatol 22:639–643PubMed

27.

Giovannoni G, Thompson AJ, Miller DH, Thompson EJ (2001) Fatigue is not associated with raised inflammatory markers in multiple sclerosis. Neurology 57:676–681PubMed

28.

Bakshi R, Miletich RS, Henschel K et al (1999) Fatigue in multiple sclerosis: cross-sectional correlation with brain MRI findings in 71 patients. Neurology 53:1151–1153PubMed

Titel: The effect of interleukin-1 blockade on fatigue in rheumatoid arthritis—a pilot study
verfasst von: Roald Omdal
Ragnar Gunnarsson
Publikationsdatum: 01.09.2005
Verlag: Springer-Verlag
Erschienen in: Rheumatology International / Ausgabe 6/2005
Print ISSN: 0172-8172
Elektronische ISSN: 1437-160X
DOI: https://doi.org/10.1007/s00296-004-0463-z

Leitlinien kompakt für die Innere Medizin

Mit medbee Pocketcards sicher entscheiden.

^{Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag}

Kostenlos registrieren

Update Innere Medizin

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen

Klimawandel und Gesundheit: Was Sie in der Hausarztpraxis wissen müssen und tun können

Springer Medizin

The effect of interleukin-1 blockade on fatigue in rheumatoid arthritis—a pilot study

Abstract

Leitlinien kompakt für die Innere Medizin

Neu im Fachgebiet Innere Medizin

Triglyzeridsenker schützt nicht nur Hochrisikopatienten

Gibt es eine Wende bei den bioresorbierbaren Gefäßstützen?

Vorsicht, erhöhte Blutungsgefahr nach PCI!

Wie managen Sie die schmerzhafte diabetische Polyneuropathie?

Update Innere Medizin

Klimawandel und Gesundheit: Was Sie in der Hausarztpraxis wissen müssen und tun können

Springer Medizin

Abstract

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 6/2005

Ochronotic arthritis: case reports and review of the literature

Multivariate analysis of biochemical markers in synovial fluid from the shoulder joint for diagnosis of rotator cuff tears

Osteoporosis fracture liaison experience: the Belfast experience

The effect of infliximab on extraintestinal manifestations of Crohn’s disease

Assessment of aortic stiffness and ventricular diastolic functions in patients with Behçet’s disease

Adenosine deaminase enzyme levels, their relation with disease activity, and the effect of colchicine on adenosine deaminase levels in patients with Behçet’s disease

Leitlinien kompakt für die Innere Medizin

Neu im Fachgebiet Innere Medizin

Triglyzeridsenker schützt nicht nur Hochrisikopatienten

Gibt es eine Wende bei den bioresorbierbaren Gefäßstützen?

Vorsicht, erhöhte Blutungsgefahr nach PCI!

Wie managen Sie die schmerzhafte diabetische Polyneuropathie?

Update Innere Medizin